Existing guidelines suggest that drug discontinuation at least 5 days before surgery, 3 4 but some patients can be safely operated after only 3 days of drug discontinuation. 5 A recent update of Society of Thoracic Surgeons guidelines 6 states, with a level of evidence IIa, that the use of platelet function tests (PFTs) is reasonable to settle timing for cardiac and non-cardiac surgery.
In previous studies, we have used multi-electrode aggregometry (MEA) as a preoperative PFT in patients undergoing cardiac surgery who are treated with thienopyridines (ticlopidine, clopidogrel, and prasugrel) or ticagrelor, anti-platelet agents that inhibit the adenosine-diphosphate (ADP)-dependent P 2 Y 12 platelet receptor. We identified a cut-off value for the ADPtest of 31 U for avoidance of excessive postoperative bleeding, 7 and
we confirmed that recovery of platelet function after drug discontinuation is highly individualized, being only partially dependent on the timing of discontinuation. 8 During cardiac surgery with cardiopulmonary bypass (CPB) thrombin is extensively generated. 9 Thrombin is a powerful platelet activator, acting on the protease-activated human platelet receptors (PARs) PAR-1 and PAR-4. PAR activation is partially dependent on P 2 Y 12 inhibition, 10 and therefore it is possible that platelet aggregation remains within an acceptable range even in the presence of strong drug-induced inhibition of P 2 Y 12 receptors. However, evidence supporting the use of PFTs before surgery is based on assessment of P 2 Y 12 activity only. 7 8 11 12 The present study assessed the association between P 2 Y 12 receptor and PAR reactivity with postoperative bleeding in patients under dual anti-platelet therapy undergoing cardiac operations with CPB. The primary endpoint was to verify the hypothesis that preoperative thrombin-dependent platelet aggregation testing allows better determination of the correct timing of surgery, avoiding the risk of excessive bleeding and also unnecessary delay.
Methods

Study design
Since 2009 patients undergoing heart operations and treated with dual anti-platelet therapy with P 2 Y 12 inhibitors not discontinued at least 1 week before operation were usually screened with a point-of-care PFT (Multiplate TM , Verum Diagnostica GmbH, Munchen, Germany) at our institution. We therefore designed a retrospective cohort study based on data stored in our institutional database and in the Multiplate database. The study was approved by our Local Ethics Committee (ASL Milano 2 Melegnano), and the need for an informed consent was waived.
Patient population and platelet function testing
For the period of January 2009 -March 2012 we retrieved data on 435 patients who received PFTs before cardiac surgery. The PFT was performed point-of-care within the operating theatre, the day before the operation, or the morning of the operation for afternoon operations. All patients were treated with thienopyridines before surgery, with discontinuation ,7 days.
PFT was performed as previously described. 7 8 Briefly, whole blood was collected into 3.0 ml tubes containing hirudin as an anti-coagulant. Three hundred microlitres of blood was added to 300 ml of 378C saline solution, and platelet aggregation was analysed after activation with ADP (ADPtest, 6.5 mM final concentration) or thrombin receptor-activating peptide (TRAP-6, TRAPtest, 32 mM final concentration). ADPtest is sensitive to ADP receptor (P 2 Y 1 and P 2 Y 12 ) inhibition induced by direct ADP receptor antagonists like thienopyridines, whereas TRAP-6 is a potent platelet activator via the thrombin-dependent PAR-1 and PAR-4 receptors. Increasing electric impedance was electronically measured for 6 min and expressed as area under the aggregation curve plotted over time [AUC, (U)] by an integrated software. Reference ranges indicated by the manufacturer were AUCs of 53 122 U for ADPtest and 94 156 U for TRAPtest. Blood collection tubes, test cells, reagents, and analysing software were all provided by the manufacturer as a part of the standard supply to our hospital and without support linked to the study.
Before 2009, it was our standard practice to interrupt thienopyridine therapy at least 5 days before operation. However, patients might be operated even without discontinuing thienopyridines if considered urgent. Starting in 2011 patients were admitted to surgery even in case of discontinuation ,5 days, in case of acceptable (.31 U) platelet function by the ADPtest. 7 If the operation was considered urgent, the patient was always admitted to surgery regardless of platelet function. TRAPtest was performed routinely until 2011, but was selectively performed according to operator choice from 2011. Operators include trained staff cardiac anaesthesiologists and a laboratory technician in charge of the point-of-care coagulation laboratory of our institution. Seventy-four patients received only an ADPtest and were excluded. The final patient population (361 subjects) received both ADPtest and TRAPtest on the same day before surgery. In case of multiple tests, the last value immediately before surgery was considered. This corresponds to a test always done within 24 h before surgery.
All patients were treated with aspirin that was not discontinued before surgery.
Data collection and definitions
All patients received tranexamic acid intra-operatively ( ); type of thienopyridine used (ticlopidine, clopidogrel, prasugrel) and date of last intake; result and date of ADPtest and TRAPtest; type of surgery; CPB duration (min); postoperative bleeding (ml in 12 postoperative h); and allogeneic blood products transfusions.
Severe bleeding was defined according to the Universal Definition of Perioperative Bleeding (UDPB) in adult cardiac surgery 13 as the presence of at least one of the following:
chest drain fluid loss .1 litre in the first 12 postoperative hours, need for surgical re-exploration, and need for .5 units of red blood cells or fresh frozen plasma. The UDPB criteria were partially applied because of absent retrospective data like delayed sternal closure; massive bleeding (defined according to the UDPB) was included in the definition of severe bleeding.
Statistical analysis
Data are presented as mean (SD) for continuous variables, and as number and percentage for categorical variables. The univariate association between continuous variables and postoperative bleeding (after testing for normality of distribution) was explored using linear or non-linear regression analyses. The association between binary categorical variables and postoperative bleeding was tested with Student's t-test. Multivariable models were based on linear regression models (stepwise forward), with inclusion of the factors that demonstrated an association with postoperative bleeding at a P value ,0.1 by univariate analysis. The diagnostic properties of PFTs for the association with severe postoperative bleeding were investigated using Receiver Operating Characteristics (ROC) analysis with c-statistics. The coordinates of the ROC curve were explored in order to identify adequate threshold for severe bleeding, using a combination of sensitivity and specificity (Youden's index, sensitivity+specificity21). For each identified threshold, statistical analysis for the association with severe bleeding was applied using Pearson's x 2 and assessing negative and positive predictive power. Analysis was done
Platelet inhibition and bleeding in cardiac surgery using SPSS 20.0 (IBM, Chicago, IL, USA). P,0.05 was considered statistically significant.
Results
General characteristics of the patient population are depicted in Table 1 . Platelet count was always .80 000 cells ml 21 .
There was a positive association between platelet count and ADPtest (P¼0.043), and positive association between platelet count and TRAPtest (P¼0.006). Both preoperative ADPtest and TRAPtest were negatively associated with postoperative bleeding (P,0.001). Other factors associated (P,0.1) with postoperative bleeding were congestive heart failure, recent myocardial infarction, diabetes mellitus (lower bleeding), type of operation (larger bleeding in all surgeries other than isolated coronary surgery), previous heart surgery (higher bleeding), and longer CPB duration (higher bleeding). Included in a multivariable model, both ADPtest (P¼0.002) and TRAPtest (P¼0.001) remained independently associated with postoperative bleeding.
The association between ADPtest, TRAPtest, and postoperative bleeding was explored using different models of linear and non-linear regression analyses. The best fit for both tests was logarithmic (Figs 1 and 2 ), demonstrating that for both tests postoperative bleeding remains substantially unchanged for even large changes in aggregometry when the test yielded results from moderately decreased to normal values. Conversely, postoperative bleeding rapidly climbs when low values of aggregometry are reached.
Severe bleeding was found in 27 (7.5%) patients. Cut-off values for the association with severe bleeding were searched by testing general accuracy of ADPtest and TRAPtest as diagnostic tests for severe bleeding using ROC analysis. For both tests general accuracy was poor (c-statistics for ADPtest: 0.62; for TRAPtest: 0.65), reflecting the nature of the relationship between PFTand bleeding, with a large zone corresponding to normal or moderately depressed platelet function where postoperative bleeding does not depend on preoperative platelet function. Based on the coordinates of the ROC curve, sensitivity and specificity, and negative and positive predictive power of different cut-off values were tested for both ADPtest and TRAPtest. The best combination of negative and positive predictive power was found for ADPtest ,22 U and TRAPtest ,75 U ( Table 2) . Both tests yielded a very good NPV (94 and 95%, respectively), with a low positive predictive value (20 and 23%). After correction for potential confounders, both threshold values identified for ADPtest and TRAPtest remained independently associated with severe bleeding (Table 3) . ADPtest and TRAPtest were tested in separate models because of their intercorrelation, with potential confounders identified in Table 1 .
The association between ADPtest and TRAPtest was explored using linear and non-linear regression analyses. The best fit was a logarithmic function (Fig. 3) . From the analysis of this relationship and based on the identified cut-off values ADPtest ,22 U demonstrated further improvement in both negative (100%) and positive (37%) predictive values for severe bleeding (Table 2) . 
Discussion
The main results of this study are that (i) patients with moderately decreased to normal values of platelet reactivity by preoperative PFT have a very low risk of severe postoperative bleeding, and (ii) low values of platelet aggregation by the ADPtest can be compensated by acceptable values of platelet aggregation by the TRAPtest. Although anti-platelet agents commonly used on top of aspirin inhibit the P 2 Y 12 receptor, our data demonstrate that their action exerts partial inhibition even PARs. TRAPtest was below the normal range in many of our patients, and there was a logarithmic relationship between P 2 Y 12 and PAR inhibition. This relationship was observed by Badr Eslam and colleagues 14 in a smaller series of patients using the same PFT technology, but these authors suggest a linear relationship in their relatively small patient population. Other studies could demonstrate that P 2 Y 12 inhibition exerts a degree of PAR-1 inhibition. 15 16 The interpretation of this phenomenon is based on the dynamic concept of platelet activation: thrombin initiates the process activating the PAR-1 and PAR-4, the activated platelets release ADP, which in turn further activates platelets through P 2 Y 12 receptors. Thrombin and ADP act synergistically in the process of platelet activation, and P 2 Y 12 receptor inhibition partially attenuates the effect of thrombin receptors activation.
The existence of a sort of 'cross-reactivity' between the P 2 Y 12 receptors and PARs receptors stresses the potential role of PAR reactivity as a factor associated with postoperative bleeding. Our data demonstrate that abnormalities in the ADPtest and the TRAPtest are associated with postoperative bleeding, and that both tests have very good negative predictive power as diagnostic tests for severe bleeding.
With respect to our previous study, 7 we found a lower threshold for the ADPtest association with severe bleeding. This could be because of two factors: the much larger patient population and the outcome (severe bleeding) had a different definition. The UDPB was not available when we performed the first study; this led to a more restrictive definition in the previous study (where excessive bleeding was defined as .0.8 litre over 12 h 21 ). Using the new definition, the ADPtest threshold decreased from 31 to 22 U. This value is close to the one of 19 U previously identified as the threshold for major bleeding events in patients undergoing percutaneous coronary intervention. 17 Another important finding is that PAR-related platelet function seems able to compensate for poor P 2 Y 12 -related function. TRAPtest ≥75 U in patients with ADPtest ,22 U has a 100% negative predictive power for severe postoperative bleeding. This information is new and clinically relevant, because application of TRAPtest in this subset of patients avoids unnecessary delay in surgical timing. In our previous study, 7 because of the relatively low number of patients, we did not investigate the combination of ADP and TRAP test for association with severe bleeding, and we could not identify the predictive power of combined ADP -TRAP test. In the present study, 45% of patients with ADPtest ,22 U have a TRAPtest ≥75 U and thus can be operated without risk of severe bleeding. Thrombin- therefore suggesting the usefulness of specific PFT tests addressing PAR function in patients receiving standard dual anti-platelet therapy.
The results of our study highlight the high negative predictive power of preoperative platelet function testing. Conversely, the positive predictive power remains remarkably low. This depends on the multifactorial nature of postoperative bleeding, where preoperative platelet function seems to underlie only a limited part of the problem. Other factors play a wellrecognized role: residual heparin, consumption of coagulation factors including fibrinogen, and surgical sources. Postoperative platelet dysfunction is also an important component of the bleeding process. We are lacking PFTperformed after operation, and therefore cannot address the potential role of postoperative PFTs. However, the purpose of the present study was to assess the usefulness of preoperative tests in order to determine the adequate time between P 2 Y 12 discontinuation and surgery, a 'modifiable' risk factor for postoperative bleeding. Conversely, post-surgery tests are more related to the choice of adequate treatment of bleeding.
A strength of our study is the definition of severe bleeding according to the UDPB, which can be applied to different institutions. There are, however, limitations in our study: the most important of which is the retrospective nature. We cannot exclude that some potential confounders were not included in our data collection; moreover, we are lacking data linking postoperative bleeding to postoperative PFTs and to other pre-and postoperative measures of haemostatic balance, like viscoelastic tests.
There are practical implications of this study. PFTs exploring P 2 Y 12 receptor function should be routinely used to assess platelet function before cardiac surgery in patients receiving dual anti-platelet therapy. Conversely, routine use of tests exploring PAR activity like the TRAPtest is likely to result in redundant information and increased costs, as already suggested in other studies. 15 Our suggestion is that only the presence of a very low level of P 2 Y 12 reactivity (by the ADPtest) justifies a second PFT test based on PAR function (like the TRAPtest). This 'sequential' combined strategy avoids unnecessary delays in surgery and allows cost-containment. PFTs are of increased interest in surgery for patients treated with P 2 Y 12 inhibitors, and their usefulness in the setting of platelet transfusions has been recently highlighted. 19 20 Additionally, new anti-platelet drugs inhibiting PARs (vorapaxar and atopaxar) will soon become available, and the TRAP test has already been used to test the platelet inhibition induced by these drugs. 21 Further studies are needed to clarify the potential role of PFTs before and after cardiac surgery as tools to establish the correct time for surgery and to guide platelet transfusion therapy.
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